# Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension

> **NCT03640312** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 62 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** QUARTET LDQT
- **DRUG:** Candesartan

## Key facts

- **NCT ID:** NCT03640312
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-30
- **Primary completion:** 2022-05-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-01-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03640312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03640312, "Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03640312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*